Sei Investments CO Allakos Inc. Transaction History

Sei Investments CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$1.02 - $3.23 $44,000 - $139,335	43,138 New	43,138 $54,000
Q2 2022 Aug 15, 2022	BUY	$2.6 - $6.14 $38,472 - $90,853	14,797 New	14,797 $46,000
Q2 2021 Aug 06, 2021	SELL	$85.37 - $114.1 $536,891 - $717,574	-6,289 Closed	0 $0
Q4 2020 Feb 08, 2021	BUY	$79.58 - $152.45 $500,478 - $958,758	6,289 New	6,289 $880,000
Q1 2020 May 14, 2020	SELL	$44.49 - $93.39 $338,301 - $710,137	-7,604 Closed	0 $0
Q4 2019 Feb 06, 2020	BUY	$66.49 - $137.73 $66,755 - $138,280	1,004 Added 15.21%	7,604 $725,000
Q3 2019 Nov 12, 2019	BUY	$31.0 - $89.73 $204,600 - $592,218	6,600 New	6,600 $519,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $108M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

Stay updated on Sei Investments CO with notifications on news.